Finanzen von Rallybio Corp (RLYB)RLYBRallybio Corp

Evaluating the bottom line, Rallybio Corp maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -4119.34%, while the net margin is -3904.72%. These profitability ratios, combined with a Return on Equity (ROE) of -14.98%, provide a clear picture of how effectively RLYB converts its operational activities into shareholder value.

In the context of the broader market, RLYB competes directly with industry leaders such as ALDX and ICCC. With a market capitalization of $89.00M, it holds a significant position in the sector. When comparing efficiency, RLYB's gross margin of 100.00% stands against ALDX's N/A and ICCC's 33.92%. Such benchmarking helps identify whether Rallybio Corp is trading at a premium or discount relative to its financial performance.

The company has shown a gross margin of 100% across recent quarters, indicating strong revenue generation relative to costs, but it also reported significant net losses, with a net income of -8,278,000 USD in the latest quarter.